Intensified glucose control in type 2 diabetes--whose agenda? (Q48751426)

15 February 2018

title

Intensified glucose control in type 2 diabetes--whose agenda? (English)

1 reference

15 February 2018

1 reference

3

Edwin A M Gale

1 reference

15 February 2018

author name string

John S Yudkin

series ordinal

1

1 reference

15 February 2018

Bernd Richter

series ordinal

2

1 reference

15 February 2018

language of work or name

English

0 references

publication date

18 November 2010

1 reference

15 February 2018

published in

The Lancet

1 reference

15 February 2018

volume

377

1 reference

15 February 2018

page(s)

1220-1222

1 reference

15 February 2018

issue

9773

1 reference

15 February 2018

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961112-9

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961112-9

7 January 2021

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961112-9

7 January 2021

Intensified glucose lowering in type 2 diabetes: time for a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961112-9

7 January 2021

Glycemic control in type 2 diabetes: time for an evidence-based about-face?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961112-9

7 January 2021

Standards of medical care in diabetes--2010.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961112-9

7 January 2021

Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961112-9

7 January 2021

Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961112-9

7 January 2021

Three-year efficacy of complex insulin regimens in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961112-9

7 January 2021

Patient perceptions of quality of life with diabetes-related complications and treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961112-9

7 January 2021

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961112-9

7 January 2021

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961112-9

7 January 2021

Dysglycaemia and risk of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961112-9

7 January 2021

Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961112-9

7 January 2021

The market in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961112-9

7 January 2021

10.1016/S0140-6736(10)61112-9

Identifiers

DOI

1 reference

15 February 2018

PubMed ID

21093903

1 reference

15 February 2018